Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary. Vertical transmission of hepatitis B virus (HBV) can occur occasionally despite vaccination of the child. This vaccination breakthrough has been associated with high maternal viraemia. We treated eight highly viraemic (HBV‐DNA ≥ 1.2 × 10 9 geq/mL) mothers with 150 mg of lamivudine daily during the last month of pregnancy. HBV‐DNA, hepatitis B surface antigen (HBsAg), anti‐HBs and anti‐HBc of their offspring were measured at birth and at 3, 6 and 12 months, respectively. Twenty‐four children, born to untreated HBsAg‐positive mothers with HBV‐DNA levels ≥1.2 × 10 9 geq/mL served as historical controls. All children received passive‐active immunization at birth and were followed‐up for 12 months. In the lamivudine group one of the eight children (12.5%) was still HBsAg and HBV‐DNA positive at the age of 12 months. All other children seroconverted to anti‐HBs and maintained seroprotection. In three children, HBV‐DNA was temporarily detected by polymerase chain reaction. In the untreated historical control group, perinatal transmission occurred in seven of 25 children (28%). In highly viraemic HBsAg‐positive mothers, reduction of viraemia by lamivudine therapy in the last month of pregnancy may be an effective and safe measure to reduce the risk of child vaccination breakthrough. This approach should be evaluated in a large controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199504000-00002 · Cited by 1,816
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Mitochondrial toxicity of antiviral drugs
Lewis, W., & Dalakas, M. C. (1995) · Nature Medicine · doi:10.1038/nm0595-417 · Cited by 770
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., Ciraru-Vigneron, N., Lacroix, C., Rouzioux, C., Mandelbrot, L., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07219-0 · Cited by 661
Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1
Mandelbrot, L. (2001) · JAMA · doi:10.1001/jama.285.16.2083 · Cited by 392
Long-term therapy of chronic hepatitis B with lamivudine
Lau, D. T.-Y., Khokhar, F. M., Doo, E., Ghany, M. G., Herion, D., Park, Y., Kleiner, D. E., Schmid, P., Condreay, L. D., Gauthier, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17912 · Cited by 348
Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects
Lorenzi, P., Spicher, V. M., Laubereau, B., Hirschel, B. J., Kind, C., Rudin, C., Irion, O. P., & Kaiser, L. (1998) · AIDS · doi:10.1097/00002030-199818000-00002 · Cited by 282
del Canho, R., Grosheide, P. M., Mazel, J. A., Heijtink, R. A., Hop, W. C. J., Gerards, L. J., de Gast, G. C., Fetter, W. P. F., Zwijneberg, J., & Schalm, S. W. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00080-7 · Cited by 190
Self-citationMoodley, J., Moodley, D., Pillay, K., Coovadia, H., Saba, J., van Leeuwen, R., Goodwin, C., Harrigan, P. R., Moore, K. H. P., Stone, C., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/314431 · Cited by 188
Protective efficacy of hepatitis B vaccines in neonates
André, F. E., & Zuckerman, A. J. (1994) · Journal of Medical Virology · doi:10.1002/jmv.1890440206 · Cited by 172
Ngui, S. L., Andrews, N. J., Underhill, G. S., Heptonstall, J., & Teo, C. G. (1998) · Clinical Infectious Diseases · doi:10.1086/514610 · Cited by 134
Ip, H. M. H., Wong, V. W., Lelie, P. N., Kuhns, M., & Reesink, H. W. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90003-2 · Cited by 126
del Canho, R., Grosheide, P. M., Schalm, S. W., de Vries, R. R. P., & Heijtink, R. A. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80494-5 · Cited by 109
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., & Tobias, H. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.021 · Cited by 558
Xu, W. ‐., Cui, Y. ‐., Wang, L., Yang, H., Liang, Z. ‐., Li, X. ‐., Zhang, S. ‐., Qiao, F. ‐., Campbell, F., Chang, C. ‐., et al. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01056.x · Cited by 387
Metadata
- Authors
- van Zonneveld, M., van Nunen, A. B., Niesters, H. G. M., de Man, R. A., Schalm, S. W., & Janssen, H. L. A.
- Venue
- Journal of Viral Hepatitis
- Publisher
- Wiley
- Published
- 2003-06-23
- Volume
- 10
- Issue
- 4
- Pages
- 294-297
- ISSN
- 1352-0504 (ISSN-L)
- 1365-2893
- OpenAlex
- W2019630600
- Cited by
- 289
- References
- 15
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.